The results of our retrospective pilot study showed that among patients with advanced NSCLC with wild-type or unknown EGFR/ALK status, kinless patients had a worse prognosis, similar to elderly patients, patients with distant metastases, and those with poor performance status, although many had started primary treatment for lung cancer. The gene discussed is ALK; the disease is lung carcinoma.